Atlantic Health System | Strategic Alliance Partners

Latest from Atlantic Health System

Dr. Haigentz on the Potential of Erlotinib and Bevacizumab in EGFR-Mutant NSCLC

November 17, 2018

Missak Haigentz, MD, chief of Hematology and Oncology at Morristown Medical Center and medical director of Atlantic Hematology and Oncology for Atlantic Medical Group at the Carol G. Simon Cancer Center, discusses the potential of erlotinib (Tarceva) and bevacizumab (Avastin) in EGFR-mutant non–small cell lung cancer (NSCLC).